This is big news...!!!!
Monday July 13, 8:51 am Eastern Time
Company Press Release
SOURCE: Bioject Medical Technologies Inc.
Bioject Enters Vaccine Agreement With Merck
PORTLAND, Ore., July 13 /PRNewswire/ -- Bioject Medical Technologies Inc. (Nasdaq:
BJCT - news), the leading manufacturer of jet injection devices for needle- free
intradermal, subcutaneous and intramuscular injections, today announced it has
entered into an agreement that provides Merck & Co. (NYSE: MRK - news) with the
rights to use its jet injection system to deliver selected Merck vaccines. The terms of
the agreement were not disclosed.
Said Jim O'Shea, chairman, president and chief executive officer of Bioject: ''This
alliance underscores the tremendous potential of our unique needle-free
technologies. The Biojector 2000 is the only needle-free injector available today
that is capable of delivering intradermal, subcutaneous and intramuscular
injections.''
O'Shea continued: ''We're delighted to be working with an industry leader such as
Merck, and are optimistic about the relationship. This agreement marks a
significant step forward in our strategy to grow through corporate partnerships
aimed at developing new applications for our technologies, and we intend to build
on this partnership and others to benefit our shareholders, employees and
customers.''
Bioject develops, manufactures and markets jet injection systems for needle-free
delivery of pharmaceutical agents. The Company's advanced injection management
system, the Biojector 2000, has received the Seal of Acceptance from the Alliance of
Children's Hospitals, Inc. The Company is developing a system for Hoffmann-La
Roche to market specifically with their products. Bioject is also developing an
ambulatory continuous blood glucose- monitoring system for diabetics through
Marathon Medical Technologies, its joint venture with Elan Corporation.
The forward-looking statements contained in this release are subject to the safe
harbor provisions of the Private Securities Litigation Reform Act of 1995. Such
forward looking statements involve known and unknown risks, uncertainties and
other factors which may cause the actual results, performance or achievements of
the company, or industry results, to be materially different from any future results,
performance, or achievements expressed or implied by such forward looking
statements. Readers of this press release are referred to the company's filings with
the Securities and Exchange Commission, including the company's Annual Report
on Form 10-K for the year ended March 31, 1998 for further discussions of factors
which could affect future results.
SOURCE: Bioject Medical Technologies Inc.
More Quotes
and News:
Bioject Medical Technologies Inc (Nasdaq:BJCT - news)
Merck & Co Inc (NYSE:MRK - news)
Related News Categories: medical/pharmaceutical
Jim |
